Stay Up-to-Date with the Latest GLP-1 News
Discover the latest news within GLP-1 therapeutics, and which sessions on our agenda will allow you to explore these topics further.
The Dawn of Multi-Agonists with Novo Nordisk’s Triple-Targeting "UBT251"
Recent Phase 2 results for Novo Nordisk’s UBT251 (a triple agonist for GLP-1, GIP, and glucagon) have shown weight loss exceeding 20% in just 24 weeks. This marks a shift from simple monotherapies to advanced multi-target compounds.
Join Cecilie Jepsen (Vice President, R&D External Innovation, Novo Nordisk) on Scientific Program Day One and open the discussion on "Unlocking the Potential of Combination Therapies".
This news directly informs the session on "Next-Generation Multi-Agonists," where the industry is moving toward unimolecular tetra-agonists designed to rival bariatric surgery.
Related Session: Unlock the Potential of Combination Therapies with Novo Nordisk
FDA Milestone with Allurion Receives Approval for its Swallowable Gastric Balloon
Allurion recently announced FDA approval for its innovative Allurion Balloon, a swallowable, procedure-less gastric balloon that deflates and passes naturally after four months. This non-invasive device is increasingly being studied in combination with GLP-1 drugs to maintain long-term weight loss.
This breakthrough highlights the summit's focus on "Next-Generation Tolerability and Delivery" to enhance patient adherence.
The Allurion approval serves as a prime case study for the session "Is There Anything GLP-1s Can't Do? Unlocking the Next Generation of Metabolic Treatments," led by Alan Baldridge (Senior Director, ICON).
Related Session: Unlocking the Next Generation of Metabolic Treatments with ICON
AstraZeneca’s Oral Leap with Elecoglipron Moves into Phase 3
AstraZeneca has officially moved its oral GLP-1 candidate, elecoglipron, into Phase 3 trials. Unlike injectables, this small molecule offers a convenient daily pill format that could drastically change patient compliance.
Alok Pachori (Medical Director, Global Development, AstraZeneca) will be speaking on "Harnessing the Gut Axis" and the emergence of oral formulations.
This news is central to the "Improving Patient Recruitment & Retention" session with Kristin Fiorino (AstraZeneca), which explores how novel delivery systems streamline drug development.
Related Sessions: Harness the Gut Axis & Improve Patient Recruitment & Retention with AstraZeneca
Eli Lilly’s "SYNERGY-Outcomes" is Shifting the Goal to Heart & Kidney Health
Eli Lilly’s ongoing SYNERGY-Outcomes trial is exploring how its dual-agonist (tirzepatide) protects the heart and kidneys beyond weight loss. Recent data suggests significant reduction in Major Adverse Kidney Events (MAKE).
Fady Botros (Associate VP, Eli Lilly) will present a dedicated session on "Unlocking Synergistic Efficacy... to Halt Cardiorenal Progression in Chronic Kidney Disease".
This trial is a cornerstone of the workshop on "Integrating MIDD & Adaptive Experimental Design for De-Risking Combinations," where experts from Merck and i2o Therapeutics will analyze these massive outcome trials.
Related Sessions: Halt Cardiorenal Progression in CKD with Eli Lilly & De-Risk Combinations with Merck & i2O Therapeutics
Beyond Metabolic with GLP-1s for Alzheimer's and Addiction
Emerging clinical trials are showing that GLP-1 receptors in the brain can reduce cravings and neuroinflammation, offering hope for treating Alzheimer's and substance use disorders.
Adriana Ramos (Principal Scientist, Sanofi) and Ashwani Singal (University of Louisville) will lead the Day Two sessions on "Extending the Therapeutic Horizon" to include neurological disorders and addiction.
This expansion is a key theme of the summit, aiming to "Broaden the therapeutic horizon" into high-growth areas like women's health and addiction recovery.
Related Session: Extend the Therapeutic Horizon with Sanofi & University of Louisville
Explore the Agenda
Hear the latest industry breakthroughs and gain exclusive insights during our packed agenda, interactive roundtables, and panel discussions.
Partner With Us
Position yourself alongside other leading solution providers to ensure your brand is at the heart of biopharma deals.
Join Biopharma Experts
Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions.